ISOPP Position Paper on the role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

The position paper developed by the Immunotherapy Task Force has been approved by the ISOPP Secretariat and published online ahead of print by the Journal of Oncology Pharmacy Practice. 

The position statement describes four key recommendations:

1) participation as an integrated, collaborative member of the multidisciplinary health care team (MHT);

2) provision of education and training for patients, students, residents, fellows and other members of the MHT;

3) involvement in clinical governance to optimize the use of immune checkpoint inhibitors and

4) involvement in research and development in the field of immunotherapy.

This paper will allow ISOPP to have engagement with other stakeholders in the field of immunotherapy, such as pharmaceutical companies.

Congratulations to the Immunotherapy Task Force - Lynne Nakashima (Chair), María Asunción Albert-Marí, Elif Aras Atik, Jared Borlagdan, Alexandre Chan, Constanza Cortés Labra, Andrea Crespo, Melanie Danilak, Mario de Lemos, Marc Geirnaert, Esin Aysel Kandemir, CheaXin Lim, Ramatu Mas'ud Alabelewe, Rina Mutiara, Karunrat Tewthanom, Andrew Walker, Barbara Yim, and Miguel Yu.

You can view the paper on the ISOPP website here.